Novel protein kinases and molecular mechanisms of autoinhibition

被引:52
作者
Cheetham, GMT [1 ]
机构
[1] Vertex Pharmaceut Europe Ltd, Abingdon OX14 4RY, Oxon, England
关键词
D O I
10.1016/j.sbi.2004.10.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
During the past year, crystal structures of the PDK-1, ITK, Aurora-A, c-KIT and FLT-3 protein kinases in complex with several ATP-competitive inhibitors have been determined. Some structures have crystallized in catalytically active conformations, whereas others appear to be in inactive or native conformations. The differences between these two classes of structures provide further understanding of how kinase activity may be self-regulated in the cellular environment and how phosphorylation can modulate signalling at a molecular level. All of these structures provide a basis for designing selective protein kinase inhibitors of use in the treatment of cancer and autoimmune disease.
引用
收藏
页码:700 / 705
页数:6
相关论文
共 35 条
[1]   Mitotic mechanics: the auroras come into view [J].
Andrews, PD ;
Knatko, E ;
Moore, WJ ;
Swedlow, JR .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (06) :672-683
[2]   Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3 [J].
Bali, P ;
George, P ;
Cohen, P ;
Tao, JG ;
Guo, F ;
Sigua, C ;
Vishvanath, A ;
Scuto, A ;
Annavarapu, S ;
Fiskus, W ;
Moscinski, L ;
Atadja, P ;
Bhalla, K .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :4991-4997
[3]   Structural basis of Aurora-A activation by TPX2 at the mitotic spindle [J].
Bayliss, R ;
Sardon, T ;
Vernos, I ;
Conti, E .
MOLECULAR CELL, 2003, 12 (04) :851-862
[4]  
Bayliss R, 2004, CELL CYCLE, V3, P404
[5]   A specific intermolecular association between the regulatory domains of a Tec family kinase [J].
Brazin, KN ;
Futton, DB ;
Andreotti, AH .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 302 (03) :607-623
[6]   Structure-based optimization of novel azepane derivatives as PKB inhibitors [J].
Breitenlechner, CB ;
Wegge, T ;
Berillon, L ;
Graul, K ;
Marzenell, M ;
Friebe, WG ;
Thomas, U ;
Schumacher, R ;
Huber, R ;
Engh, RA ;
Masjost, B .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1375-1390
[7]   Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors [J].
Brown, K ;
Long, JM ;
Vial, SCM ;
Dedi, N ;
Dunster, NJ ;
Renwick, SB ;
Tanner, AJ ;
Frantz, JD ;
Fleming, MA ;
Cheetham, GMT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (18) :18727-18732
[8]   Crystal structure of aurora-2, an oncogenic serine/threonine kinase [J].
Cheetham, GMT ;
Knegtel, RMA ;
Coll, JT ;
Renwick, SB ;
Swenson, L ;
Weber, P ;
Lippke, JA ;
Austen, DA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (45) :42419-42422
[9]   Therapeutically targeted anticancer agents:: Inhibitors of receptor tyrosine kinases [J].
García-Echeverria, C ;
Fabbro, D .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (03) :273-283
[10]   The structural basis for autoinhibition of FLT3 by the juxtamembrane domain [J].
Griffith, J ;
Black, J ;
Faerman, C ;
Swenson, L ;
Wynn, M ;
Lu, F ;
Lippke, J ;
Saxena, K .
MOLECULAR CELL, 2004, 13 (02) :169-178